Modality
Gene Therapy
MOA
C5i
Target
CDK4/6
Pathway
Hedgehog
MDDObesity
Development Pipeline
Preclinical
Jan 2020
→ Apr 2029
PreclinicalCurrent
NCT08467084
1,684 pts·MDD
2024-04→2029-04·Not yet recruiting
NCT08491423
890 pts·MDD
2020-01→2026-07·Not yet recruiting
2,574 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-07-264mo awayInterim· MDD
2029-04-013.0y awayInterim· MDD
Trial Timeline
2020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
Preclinical
Not yet…
Preclinical
Not yet…
Catalysts
Interim
2026-07-26 · 4mo away
MDD
Interim
2029-04-01 · 3.0y away
MDD
Not yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08467084 | Preclinical | MDD | Not yet recr... | 1684 | UPDRS |
| NCT08491423 | Preclinical | MDD | Not yet recr... | 890 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| Motavorutinib | Amgen | Phase 3 | CDK4/6 | |
| Ribozanubrutinib | Regeneron | Phase 1 | CDK4/6 | |
| MRN-5715 | Moderna | NDA/BLA | CDK4/6 | |
| Rimabrutinib | Madrigal Pharma | Phase 1/2 | GPRC5D | |
| Elralucimab | Axsome | Phase 2 | CDK4/6 | |
| XEN-577 | Xenon Pharma | Phase 2/3 | C5 | |
| Rimanaritide | Agios | Phase 1 | CDK4/6 | |
| EXA-4696 | Exscientia | Phase 2/3 | KRASG12C | |
| Lisosotorasib | Sobi | Phase 2/3 | CDK4/6 |